The Journal of Immunology, Vol 157, Issue 5 1973-1980, Copyright © 1996 by American Association of Immunologists

ARTICLES

Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity

DO Willenborg, MA Staykova and M Miyasaka
Woden Valley Hospital, Canberra, Australia.

Resistance to autoimmune encephalomyelitis was induced by s.c. infusion of myelin basic protein (MBP) in saline in combination with i.p. injections of anti-CD11a (LFA-1) mAbs. This treatment induces resistance to EAE induction, which appears early and persists for at least one month after treatment. Some MBP-CFA-challenged resistant rats showed minimal inflammation in the central nervous system, which was, however, confined to the meninges of the lower spinal cord. Examination of the immune status of MBP-anti-LFA-1 treated rats before encephalitogenic challenge failed to reveal any priming when assessed by Ag driven proliferation and cytokine production by lymphoid cells, and by circulating Ab production. Following challenge of protected rats, lymph node cell proliferation to MBP was unaltered, indicating that reactive cells had not been deleted or energized. Resistance could not be transferred with lymphoid cells from treated rats nor abrogated by cyclophosphamide treatment. In treated rats following challenge, there was a shift in the isotype of anti-MBP Ab produced, from an IgG2a:IgG1 ratio of 2:1 to 1:1, due to an increase in IgG1 production, indicating a possible bias towards a nonpathogenic Th2 CD4+ T cell response. The IgG1 Ab was detected early after challenge suggesting that pretreatment had indeed primed the animals, and had primed them to go down the Th2 pathway following encephalitogenic challenge. The ability to divert immune reactivity from a destructive to a nondestructive response could have important therapeutic implications for autoimmune disease.

This article has been cited by other articles:

				S. S. Smith and S. R. Barnum Differential expression of 2-integrins and cytokine production between {gamma}{delta} and {alpha} T cells in experimental autoimmune encephalomyelitis J. Leukoc. Biol., January 1, 2008; 83(1): 71 - 79. [Abstract] [Full Text] [PDF]

				A. M. de Mestre, M. A. Staykova, J. R. Hornby, D. O. Willenborg, and M. D. Hulett Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4+ T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene1 J. Leukoc. Biol., November 1, 2007; 82(5): 1289 - 1300. [Abstract] [Full Text] [PDF]

				D. C. Bullard, X. Hu, J. E. Adams, T. R. Schoeb, and S. R. Barnum p150/95 (CD11c/CD18) Expression Is Required for the Development of Experimental Autoimmune Encephalomyelitis Am. J. Pathol., June 1, 2007; 170(6): 2001 - 2008. [Abstract] [Full Text] [PDF]

				S.-L. Tan, J. Zhao, C. Bi, X. C. Chen, D. L. Hepburn, J. Wang, J. D. Sedgwick, S. R. Chintalacharuvu, and S. Na Resistance to Experimental Autoimmune Encephalomyelitis and Impaired IL-17 Production in Protein Kinase C{theta}-Deficient Mice. J. Immunol., March 1, 2006; 176(5): 2872 - 2879. [Abstract] [Full Text] [PDF]

				K. Soda, Y. Kano, T. Nakamura, K. Kasono, M. Kawakami, and F. Konishi Spermine, a Natural Polyamine, Suppresses LFA-1 Expression on Human Lymphocyte J. Immunol., July 1, 2005; 175(1): 237 - 245. [Abstract] [Full Text] [PDF]

				A. M. de Mestre, L. M. Khachigian, F. S. Santiago, M. A. Staykova, and M. D. Hulett Regulation of Inducible Heparanase Gene Transcription in Activated T Cells by Early Growth Response 1 J. Biol. Chem., December 12, 2003; 278(50): 50377 - 50385. [Abstract] [Full Text] [PDF]

				T.-L. Hsu, Y.-C. Chang, S.-J. Chen, Y.-J. Liu, A. W. Chiu, C.-C. Chio, L. Chen, and S.-L. Hsieh Modulation of Dendritic Cell Differentiation and Maturation by Decoy Receptor 3 J. Immunol., May 15, 2002; 168(10): 4846 - 4853. [Abstract] [Full Text] [PDF]